APA (7th ed.) Citation

PS, P., SK, B., GM, C., KU, E., AG, J., EF, L., . . . WC, W. (2023). Safety Endpoints With Vadadustat Versus Darbepoetin Alfa in Patients With Non-Dialysis-Dependent CKD: A Post Hoc Regional Analysis of the PRO2TECT Randomized Clinical Trial of ESA-Treated Patients. Kidney medicine, 5(7), 100667. https://doi.org/10.1016/j.xkme.2023.100667

Chicago Style (17th ed.) Citation

PS, Parfrey, et al. "Safety Endpoints With Vadadustat Versus Darbepoetin Alfa in Patients With Non-Dialysis-Dependent CKD: A Post Hoc Regional Analysis of the PRO2TECT Randomized Clinical Trial of ESA-Treated Patients." Kidney Medicine 5, no. 7 (2023): 100667. https://doi.org/10.1016/j.xkme.2023.100667.

MLA (9th ed.) Citation

PS, Parfrey, et al. "Safety Endpoints With Vadadustat Versus Darbepoetin Alfa in Patients With Non-Dialysis-Dependent CKD: A Post Hoc Regional Analysis of the PRO2TECT Randomized Clinical Trial of ESA-Treated Patients." Kidney Medicine, vol. 5, no. 7, 2023, p. 100667, https://doi.org/10.1016/j.xkme.2023.100667.